CN105837646A - Flavonoid new chemical entity, composition and use - Google Patents
Flavonoid new chemical entity, composition and use Download PDFInfo
- Publication number
- CN105837646A CN105837646A CN201510024470.6A CN201510024470A CN105837646A CN 105837646 A CN105837646 A CN 105837646A CN 201510024470 A CN201510024470 A CN 201510024470A CN 105837646 A CN105837646 A CN 105837646A
- Authority
- CN
- China
- Prior art keywords
- gained
- hydrate
- hesperidin
- filter
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 25
- 229930003935 flavonoid Natural products 0.000 title abstract description 4
- 150000002215 flavonoids Chemical class 0.000 title abstract description 4
- 235000017173 flavonoids Nutrition 0.000 title abstract description 4
- 229940127285 new chemical entity Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 61
- 230000033228 biological regulation Effects 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000008280 blood Substances 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 230000004224 protection Effects 0.000 claims abstract description 9
- 208000014617 hemorrhoid Diseases 0.000 claims abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 claims abstract description 5
- 206010047623 Vitamin C deficiency Diseases 0.000 claims abstract description 5
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 208000006673 asthma Diseases 0.000 claims abstract description 5
- 201000002816 chronic venous insufficiency Diseases 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 230000036039 immunity Effects 0.000 claims abstract description 5
- 210000004185 liver Anatomy 0.000 claims abstract description 5
- 208000026435 phlegm Diseases 0.000 claims abstract description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 5
- 208000010233 scurvy Diseases 0.000 claims abstract description 5
- 201000002282 venous insufficiency Diseases 0.000 claims abstract description 5
- 206010025282 Lymphoedema Diseases 0.000 claims abstract description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- 208000002502 lymphedema Diseases 0.000 claims abstract description 3
- 206010062198 microangiopathy Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 210000001364 upper extremity Anatomy 0.000 claims abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 150000003254 radicals Chemical class 0.000 claims abstract 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 152
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 126
- 229940025878 hesperidin Drugs 0.000 claims description 126
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 124
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 124
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 124
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 124
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 123
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 86
- 239000007787 solid Substances 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 73
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 66
- 239000000706 filtrate Substances 0.000 claims description 64
- 238000001914 filtration Methods 0.000 claims description 61
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 56
- 238000003756 stirring Methods 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000013078 crystal Substances 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 30
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims description 28
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims description 28
- 229960004352 diosmin Drugs 0.000 claims description 28
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims description 28
- 238000001556 precipitation Methods 0.000 claims description 27
- -1 flavone compound Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 22
- 239000002244 precipitate Substances 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 20
- 150000008064 anhydrides Chemical class 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 19
- 150000002576 ketones Chemical class 0.000 claims description 18
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical class [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 16
- 230000008025 crystallization Effects 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 15
- 239000011707 mineral Substances 0.000 claims description 15
- 238000001953 recrystallisation Methods 0.000 claims description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 14
- 230000002378 acidificating effect Effects 0.000 claims description 14
- 150000007524 organic acids Chemical class 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- 150000002825 nitriles Chemical class 0.000 claims description 9
- 239000001117 sulphuric acid Substances 0.000 claims description 9
- 235000011149 sulphuric acid Nutrition 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 150000001924 cycloalkanes Chemical class 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 claims description 4
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000000767 anti-ulcer Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 150000005829 chemical entities Chemical class 0.000 claims description 4
- 230000002633 protecting effect Effects 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 230000004223 radioprotective effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010023215 Joint effusion Diseases 0.000 claims description 2
- 208000005230 Leg Ulcer Diseases 0.000 claims description 2
- 201000001819 hydrarthrosis Diseases 0.000 claims description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 9
- 229930003944 flavone Natural products 0.000 claims 9
- 235000011949 flavones Nutrition 0.000 claims 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 3
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 6
- 239000008103 glucose Substances 0.000 abstract description 6
- 208000025865 Ulcer Diseases 0.000 abstract description 5
- 231100000397 ulcer Toxicity 0.000 abstract description 5
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- 206010007191 Capillary fragility Diseases 0.000 abstract 1
- 206010014970 Ephelides Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000003260 anti-sepsis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000003141 lower extremity Anatomy 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 239000000047 product Substances 0.000 description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 239000008108 microcrystalline cellulose Substances 0.000 description 11
- 235000011121 sodium hydroxide Nutrition 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 239000007779 soft material Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 229940023488 pill Drugs 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000006196 drop Substances 0.000 description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002076 thermal analysis method Methods 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000005374 membrane filtration Methods 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 5
- 244000152526 Agathosma crenulata Species 0.000 description 4
- 235000013388 Agathosma crenulata Nutrition 0.000 description 4
- 235000009269 Barosma crenulata Nutrition 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940062650 buchu Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004455 differential thermal analysis Methods 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 240000001592 Amaranthus caudatus Species 0.000 description 3
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 208000000474 Poliomyelitis Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 239000004178 amaranth Substances 0.000 description 3
- 235000012735 amaranth Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000009519 contusion Effects 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000029865 regulation of blood pressure Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003684 drug solvent Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000005220 pharmaceutical analysis Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- YCHKKRJCPBFHAV-UHFFFAOYSA-N C(C)(=O)O.SNC(=N)N Chemical compound C(C)(=O)O.SNC(=N)N YCHKKRJCPBFHAV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000004182 Congenital stromal corneal dystrophy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical class ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical compound NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960001768 buspirone hydrochloride Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- GOADIQFWSVMMRJ-UPGAGZFNSA-N dapagliflozin propanediol monohydrate Chemical compound O.C[C@H](O)CO.C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl GOADIQFWSVMMRJ-UPGAGZFNSA-N 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229940026231 erythorbate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- KWUZCAVKPCRJPO-UHFFFAOYSA-N n-ethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(NCC)=CC=C1C1=NC2=CC=C(C)C=C2S1 KWUZCAVKPCRJPO-UHFFFAOYSA-N 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005619 thermoelectricity Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ZIWHWEYDKGWAOG-ZIDSAKIASA-H tricalcium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO ZIWHWEYDKGWAOG-ZIDSAKIASA-H 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a flavonoid new chemical entity, which has little moisture absorption and good storage stability, and is applicable to preparation of food or health food or drugs for reduction of capillary fragility, treatment or prevention of chronic venous insufficiency, hemorrhoid, scurvy, venous lower limb ulcer, premenstrual syndrome, diabetics' microangiopathy and secondary upper limb lymphedema, cardiovascular diseases, blood glucose and lipid regulation, antisepsis and inflammation reduction, virus resisting, cancer resisting, immunity adjustment, radiation protection, liver protection, rheumatoid arthritis or arthritis resisting, ulcer resisting, phlegm eliminating, asthma relieving, black spots, freckles, free radical resistance, and oxidation resistance.
Description
Technical field
The present invention relates to pharmaceutical technology field, be specifically to provide chromocor derivative, a kind of vitamin medicaments
The noval chemical compound entity of Hesperidin and compositions and preparation thereof and purposes.
Background technology
The polymorphic of chemicals has critical role in drug research.At field of pharmacology, drug crystal forms and medicine
The research work of hydrate or drug solvent compound has been listed in country 12 great new drug initiative science and technology key special subjects
Research range.The solvated compounds of compound includes hydrate the most being produced and apply in medicine very early,
Such as the antitumor drug cyclophosphamide that American Pharmacopeia 36 editions, European Pharmacopoeia 8.1 editions and Chinese Pharmacopoeia 2010 editions record
Room temperature exists with monohydrate form at solid, and this chemical entities begins to lose water of crystallization at about 40 DEG C, 72 DEG C
Left and right just loses whole water of crystallization.Since nearest more than 20 years, not only there is the different crystal forms of same molecular formula medicine
Constantly it is found, and there is same parent but the research of different molecular formula drug solvent compound the most constantly obtains new
Progress.Even regulation hypoglycemic medicament dapagliflozin is all studying the medicine system with dapagliflozin propylene glycol hydrate as core
Agent, although the toxicity of propylene glycol is more than water.
Heat analysis method has important value and status in material science, chemistry or pharmaceutical analysis etc., can individually use
Come detection compound polymorphic or during crystal formation change (Li Zengyu, " heat analyze ", publishing house of Tsing-Hua University,
In August, 1987 first edition).Differential thermal analysis (DTA) is the analysis method more commonly used, and it can be not only used for determining of material
Property differentiate it can also be used to quantitative analysis, in the international hot analysis meeting of Second Committee of nineteen sixty-eight, just by Barta etc.
It is used for identifying unknown compound.The pharmacopeia of external many countries records differential thermal analysis already, and the method is particularly with tool
The advantage that the discriminating of the same compound of different crystal forms has uniqueness.Before more than ten years, differential thermal analysis not only exists in China
Chemical industry, pharmacy system are the most widely used, and also begin in complicated TCD identification application (Zhang Hanming, etc.,
The differential thermal analysis research of Margarita powder and adulterant thereof, Chinese patent medicine, 1999,21 (4): 173-175).In crystal formation is studied, differential
Scanning (DSC) can complete the multinomial researchs such as pharmaceutical purity assessment, discriminating, polycrystalline state analysis, and (Zhu Bing, Liu Ji great waves .DSC exists
Application in pharmaceutical analysis, process industry, 2008,15:64-66), (Lin Kejiang, Chen Wei, You Qidong. means of differential scanning calorimetry
Method detection Nateglinide polymorphic, Acta Pharmaceutica Sinica, 2002,37 (1): 46-49).And the polymorphic of medicine not rare or
Expensive solvent could be prepared, meaning can be exceeded by conventional solvent, temperature, time etc. or other trickle change
Material obtain compound polymorphic (Du Qing, its energy flat. the polymorphic research of buspirone hydrochloride, China Medicine University is learned
Report, 2000,31 (2): 102-104).At hot analysis field, dividing of compound is given in the combination of TG-DTA or TG-DSC especially
Analysis brings more convenient.
Hesperidin had both belonged to vitamin drug, also served as the additive of food, Hesperidin energy hyaluronidase inhibitor,
Reduce the saturating property of blood capillary and the fragility of capillary wall, protect blood capillary, prevent the effect that microvascular is hemorrhage;
Can be used for multiple EXUDATIVE DISEASES, as edema, hemorrhage, hypertension, diabetes, chronic venous insufficiency, hemorrhoid,
Vitamin C deficiency, various ulcer and blood vessel contusion etc.;Have simultaneously antiinflammatory, antioxidation, antibacterial, anticancer, regulation immunity,
Radioprotective, protection cardiovascular system, the liver protecting, resisting rheumatoid arthritis or arthritis, antiviral (include list
Pure property herpesvirus, simplex type I virus, parainfluenza 3 type virus, poliomyelitis I type virus, respiratory tract close spore
Precursor virus, simplex type I virus, rotavirus etc. have inhibitory action), antiulcer, eliminate the phlegm, relieving asthma, blood pressure and blood lipoid
Regulation, blood pressure regulating, blood circulation healthy, to Hydroxyl Radical Scavenging and antioxidation, body regulation,
Treatment dermatosis aspect effect such as black speck, freckle.Presently disclosed document only report Hesperidin [molecular formula:
C28H34O15,Molecular weight: 610.56, CAS:520-26-3], [list of references 1, Zhu Rongli, etc., Pericarpium Citri junoris in Pericarpium Citri Reticulatae
The research of glycosides extraction process, food and fermentation industries, the 6th phase in 2012,57-60 page;Document 2, He Lina, leaf
China, Guo Fang is powerful, Hesperidin analysis technique study, Chemical Industry in Guangzhou, and 2012,40 (14): 126-128;Document 3, Qian Junzhen
Wang Baichu, the Advance on Pharmacological Activities of Hesperidin, research and development of natural products, CSCD the 1st phase-page in 2010,
Page totally 5;Document 4, Dong Songgao Hui Yuanwuli army, the pharmacology activity research progress of Hesperidin, contemporary Chinese Chinese medicine,
2006,8(7):25-27;Document 5, Bears Li Lijun Wang Wen, etc., the Hesperidin therapeutical effect to collagen-induced arthritis in rats
And Partial Mechanism, Medical University Of Anhui's journal, 2011,46 (10): 1013-1017;Document 6, Li Wei, Liu Juan, Liu Gan,
Li Jun, Hesperidin to the protective effect of acute chemical hepatic injury mice and mechanism, Medical University Of Anhui's journal,
2010,45(3):346-350;] open source literature also reports that Hesperidin is used for preparing the flavonoid such as hesperidin methyl, diosmin
Derivant;But up to the present, the most still there is no the hesperidin crystal hydrate of the disclosed document report present invention
[C28H34O15·n H2O, wherein n=0.75,1.0] and its production and use.
Summary of the invention
Involved in the present invention is chromocor derivative, energy hyaluronidase inhibitor, reduces the saturating property of blood capillary and hair
The fragility of thin blood vessel wall, protects blood capillary, prevents the effect that microvascular is hemorrhage;Can be used for multiple exudative disease
Disease, such as edema, hemorrhage, hypertension, diabetes, chronic venous insufficiency, hemorrhoid, vitamin C deficiency, various ulcer
With blood vessel contusion etc.;There is antiinflammatory, antioxidation, antibacterial, anticancer, regulation immunity, radioprotective, the protection heart simultaneously
Vascular system, the liver protecting, resisting rheumatoid arthritis or arthritis, antiviral (include herpes simplex virus,
Simplex type I virus, parainfluenza 3 type virus, poliomyelitis I type virus, respiratory tract close spore precursor virus, simplex type I disease
Poison, rotavirus etc. have inhibitory action), antiulcer, eliminate the phlegm, relieving asthma, the regulation of blood pressure and blood lipoid, blood pressure regulating,
Blood circulation is healthy, to Hydroxyl Radical Scavenging and antioxidation, body regulation, the treatment skin such as black speck, freckle
The hesperidin derivative of skin disease aspect effect, i.e. hesperidin crystal hydrate and preparation thereof and purposes, its molecular formula is
[C28H34O15·n H2O, wherein n=0.75,1.0].
The hesperidin crystal hydrate containing water of crystallization that the present invention obtains, it is surprising that the orange containing water of crystallization
Skin glycosides hydrate low in hygroscopicity is in Hesperidin anhydride, and the Hesperidin hydrate containing water of crystallization is than Hesperidin anhydride more
The existence that energy is stable, it is simple to store and transport, it is easy to make preparation.Additionally, the deliquescence of anhydride makes when processing
Air to be completely cut off prevents adhesion etc., and crystalline hydrate has good sliding, thus improves grasping of preparation
The property made.Furthermore, crystalline solid has higher than amorphous form and the chemical stability of low-crystallinity form and physically stable
Property, they can also behave as hygroscopicity, bulk properties and or the mobility improved.
Distinctive, the heat of the hydrate of the present invention is analyzed (TG-DTA etc.) collection of illustrative plates and be can be seen that at about 50~130 DEG C
Weightless platform there is strong corresponding endothermic peak, thermal analysis curue spectrum demonstrates hesperidin crystal hydrate
[C28H34O15·0.75H2O]、[C28H34O15·H2O], measure moisture result and hot analysis result phase with Karl_Fischer method
It coincide.
The polymorphic of chemicals has critical role in drug research, the useful chemical combination on the medicine of new crystal
The discovery of thing provides new chance once improving the action characteristic of drug products, and it expands formulation science man design example
The storehouse of the material obtained as having the pharmaceutical dosage form of the medicine of targeted release profile or other desired characteristic, this area
Need hesperidin crystal hydrate or its polymorph.
It is surprising that distinctive, the heat of the hesperidin crystal hydrate of the present invention analyze (TG-DSC or
TG-DTA) having the endothermic peak of correspondence under the weightless platform of collection of illustrative plates, thermal analysis curue spectrum demonstrates hesperidin crystal hydrate
Corresponding characteristic etc..
The hesperidin crystal hydrate of the present invention, for off-white color to pale yellow powder, energy stable storage.The present invention is real
Execute that hesperidin crystal hydrate sample prepared by example 1-3 method is the most airtight is accelerated stability test in cillin bottle,
With reference to the content assaying method of the China National Drug Standard [WS-10001-(HD-0489)-2002] of Hesperidin, with Pericarpium Citri junoris
Glycosides anhydride is reference substance, and mensuration is prepared by various embodiments of the invention 1, embodiment 2 and embodiment 3 method
Hesperidin crystal hydrate, it was thus unexpectedly found that the content of the Hesperidin hydrate of the present invention was at 0 month to 6 months
Not having significant change (30 DEG C, under RH75%) before and after in, be all higher than 98%, its color and outward appearance are also without significant change.Will
Hesperidin crystal hydrate and Hesperidin anhydride sample carry out drawing moist test, take Hesperidin anhydride and the present invention
Hydrate about 2g, is placed in the surface plate of dry constant weight, precise weighing, 25 DEG C, relative humidity be 75%, respectively
In test 0h and 20h sampling, calculate the percentage rate drawing wet weightening finish, result display embodiment 1, embodiment 2 and enforcement
The percentage rate of the sample weightening finish of example 3 is respectively 0.39%, 0.12%, 0.45%, and the percentage rate of anhydride weightening finish reaches
1.79%, its difference highly significant, result shows, Hesperidin anhydride draws moist more much higher than the hydrate of the present invention,
The hesperidin crystal hydrate of the present invention can preferably storage-stable.
Hesperidin crystal hydrate preparation method is selected from:
Method A., in reaction vessel, adds the dry Pericarpium Citri junoris powder of the pulverizing of constant weight, adds 3-60 times amount (bulking value
Than=gram: milliliter) water, C1-C6Low mass molecule alcohol (such as methanol, ethanol, isopropanol, butanol etc.), in acetone
One or more soak and by ultrasonic extraction or microwave extraction 0.1-2 hour, then adds saturated limewater, hydroxide
One or more in sodium solution, potassium hydroxide solution, sodium carbonate liquor, stirring, control pH and be about 9-13, so
Extract or microwave extraction 0.1-3 hour in immersion and with ultrasonic assistant, filter separating solid substances, obtain the filter of Part I
Liquid and Part I filtering residue;The filtrate of gained Part I is with mineral acid or organic acid such as dilute hydrochloric acid, sulphuric acid, phosphoric acid
Solution, regulates pH to 4~7, places, makes precipitation fully separate out, and filters, the precipitate of Part I filtrate;Gained
Part I filtering residue is again with the water of 2-30 times amount, C1-C6Low mass molecule alcohol (such as methanol, ethanol, isopropanol etc.), acetone
In one or more in soak ultrasonic extraction or microwave extraction 0.1-2 hour, then add saturated limewater, hydroxide
One or more in sodium solution, potassium hydroxide solution, sodium carbonate liquor, stirring, control pH and be about 9-13, so
Soak and by ultrasonic extraction or microwave extraction 0.1-2 hour, filter, the filtrate of gained Part II with hydrochloric acid, sulphuric acid,
The mineral acids such as phosphoric acid or organic acid soln, regulate pH to 4~7, places, makes precipitation fully separate out;Filter (sucking filtration or
Centrifugal filtration etc.), obtain the precipitate of Part II filtrate;Collect Part I filtrate and the precipitate of Part II filtrate,
It is washed to weakly acidic pH, obtains wet solids;
By in gained solids saturated limewater solution, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor
One or more dissolve, add the 20 of 2-40 times amount~the C of 60%1-C6Low mass molecule alcohol (such as methanol, ethanol, isopropyl
Alcohol), acetone or water, stirring, place, filter, gained filtrate is with mineral acids such as dilute hydrochloric acid, sulphuric acid, phosphoric acid or has
Machine acid solution, regulate pH to 4~7,25 DEG C are arranged below, make precipitation fully separate out, gained precipitate is washed with water to
Weakly acidic pH, then use C1-C6Low mass molecule alcohol, C2-C8Low molecule ether, C3-C8Low molecule ketone, C2-C8Low molecule ester,
C4-C10Low molecule alkane or cycloalkane, petroleum ether, C1-C6Low molecule halogenated hydrocarbons, including dichloromethane, two chloroethenes
The abundant rinse of one or more in alkane, chloroform etc. 1~10 times, filter, gained solid add appropriate organic solvent first
In amide, DMF (DMF), one or more, after being stirred to dissolve, add proper amount of active carbon,
Stir about 15-60 minute, crosses and filters to remove activated carbon, by gained filtrate water, C1-C6Low mass molecule alcohol, C2-C6Low
Level nitrile, C3-C8Low molecule ketone in one or more carry out crystallization operation, 20~about-25 DEG C placements, be preferable over 10~
About-15 DEG C placements, make precipitation fully separate out, and filter, with water, C1-C6Low mass molecule alcohol washing solid 1-8 time, take out
Filter, by gained solid with in appropriate Methanamide, DMF (DMF), DMSO one or more,
After being stirred to dissolve, add proper amount of active carbon, stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water,
C1-C6Low mass molecule alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out recrystallization operation,
So can carry out one or many recrystallization operation, 20~about-25 DEG C placements further in accordance with the law, be preferable over 10~-10 DEG C
Left and right is placed, and makes solid fully separate out, and filters, with water, C1-C6Low mass molecule alcohol, C3-C8Low molecule ketone, C2-C8
Low molecule ether, C2-C8Low molecule ester, C4-C10Low molecule alkane or cycloalkane, petroleum ether, C1-C6Low molecule halogen
Wash solid 1-8 time for hydrocarbon, filter, gained solids is made thinner in being dried, obtain hesperidin crystal hydrate;Wherein,
Frequency during supersound extraction can be between 10kHz-2000kHz, the power of microwave extraction can be
Between 100W-1000W;Sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor concentration generally within 4M;
The concentration of the mineral acids such as hydrochloric acid, sulphuric acid, phosphoric acid or organic acid soln is generally within 6M, more preferably within 3M.
Or method B. is in reaction vessel, add the dry Pericarpium Citri junoris powder of the pulverizing of constant weight, add 3-60 times amount (weight
Volume ratio=gram: milliliter) water, C1-C6Low mass molecule alcohol (as methanol, ethanol, isopropanol, butanol etc.) soak
Extract 0.5-4 hour, then add in saturated limewater, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor
One or more, stirring, control pH=10-13, such soak extraction 1-4 hour, filter separating solid substances, gained the
The filtrate of a part, with mineral acid or organic acid solns such as dilute hydrochloric acid, sulphuric acid, phosphoric acid, regulates pH to 4~7, places,
Precipitation is made fully to separate out;Gained Part I filtering residue extracts with the water soaking of 2-30 times amount again, then add saturated limewater,
One or more in sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor, stirring, control pH=10-13,
So soak extraction 1-4 hour, filters, and the filtrate of gained Part II is with mineral acids such as dilute hydrochloric acid, sulphuric acid, phosphoric acid
Or organic acid soln, regulate pH to 4~7, place, make precipitation fully separate out;Filter, collect Part I filtrate and
The precipitate of Part II filtrate, is washed to weakly acidic pH, obtains wet solids;
By gained solids use, saturated limewater solution, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor
In one or more dissolve, add the 20 of 2-60 times amount~the C of 60%1-C6Low mass molecule alcohol (such as methanol, ethanol, different
Propanol), acetone or water, stirring, place, filter, gained filtrate adds up the activated carbon (body of the about 0.01-3% of amount of liquid
Long-pending weight ratio=milliliter: gram), stir about 10-60 minute, sucking filtration, gained filtrate is with dilute hydrochloric acid, sulphuric acid, phosphoric acid
Deng mineral acid or organic acid soln, regulating pH to 4~7,25 DEG C arranged below, makes precipitation fully separate out, and is sunk by gained
Shallow lake thing washes with water to weakly acidic pH, then uses C1-C6Low mass molecule alcohol, C2-C8Low molecule ether, C3-C8Low molecule ketone,
C2-C8Low molecule ester, C4-C10Low molecule alkane or cycloalkane, petroleum ether, C1-C6Low molecule halogenated hydrocarbons, including two
One or more abundant rinses 1 in chloromethanes, dichloroethanes, chloroform etc.~10 times, filter, add suitable by gained solid
The organic solvent DMSO (dimethyl sulfoxide) of amount, Methanamide, in DMF (DMF) a kind of or
Several, after being stirred to dissolve, add activated carbon (weight of activated carbon and the liquor capacity of the about 0.01-3% of total amount of liquid
Than=gram: milliliter), stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water, C1-C6Low point
Sub-alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out crystallization operation, 20~-25 DEG C of left sides
Right placement, is preferable over 10~about-15 DEG C placements, makes precipitation fully separate out, and filters, with water, C1-C6Low mass molecule alcohol
Washing solid 1-8 time, filters, by gained solid appropriate DMSO, Methanamide, DMF (N, N-dimethyl methyl
Amide) in one or more, after being stirred to dissolve, add the activated carbon (volume weight of the about 0.01-3% of total amount of liquid
Ratio=milliliter: gram), stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water, C1-C6Low point
Sub-alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out recrystallization operation, may be used the most in accordance with the law
Carry out one or many recrystallization operation further, in 20~about-25 DEG C placements, be preferable over 10~about-10 DEG C placements,
Make solid fully separate out, filter, with water, C1-C6Low mass molecule alcohol, C3-C8Low molecule ketone, C2-C8Low molecule
Ether, C2-C8Low molecule ester, C4-C10Low molecule alkane or cycloalkane, petroleum ether, C1-C6In low molecule halogenated hydrocarbons
One or more washing solids 1-10 time, filter, make thinner dry by gained solids, obtain hesperidin crystal hydrate.
Wherein, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor concentration generally more preferably within 4M;Hydrochloric acid,
The concentration of the mineral acid such as sulphuric acid, phosphoric acid or organic acid soln is generally within 6M, more preferably within 3M.
Crystallization or the recrystallization solvent of product of the present invention preferably are selected from: water and methanol, ethanol, isopropanol, acetonitrile, ether,
Acetone, hexone, dichloromethane, DMSO (dimethyl sulfoxide), Methanamide, DMF (N, N-dimethyl formyl
Amine) etc. in one or more.
Lower alcohol or the carbon number of low mass molecule alcohol in the present invention are defined as C1-C6(that is: the alcohol of 1-6 carbon atom),
Such as methanol, ethanol, isopropanol, butanol etc.;C2-C6The carbon number of rudimentary nitrile be defined as C2-C6, as acetonitrile,
Propionitrile etc.;C3-C8Low molecule ketone be defined as the ketone of 3-8 carbon atom, including acetone, butanone, pentanone, hexanone,
Hexone etc.;The carbon number of rudimentary ether or low molecule ether is defined as C2-C8, such as ether, diisopropyl ether, butyl ether etc.;Close
It is described as " low molecule ", " rudimentary " as long as the labeling method of the amount of carbon atom of compound is the application's in any kind
Text occurs once, the carbon number of other any unmarked similar compound being described as " low molecule " with
The quantity indicated is consistent.
The drying mode of the product of the present invention can be that (1 hour arrives in different temperatures (such as 10-80 DEG C), drying time
A few days) or with other desiccant (including silica gel, phosphorus pentoxide, anhydrous calcium chloride, anhydrous sodium sulfate etc.)
Under environmental condition or use the mode of normal pressure or decompression that last product is dried.Its baking temperature is preferably 78
Within DEG C.
The preparation of Hesperidin anhydride can be obtained through different drying meanss by the crystalline hydrate of the present invention, and its preparation can
In different temperatures (such as 40-100 DEG C, preferably 60-95 DEG C), drying time (a few hours are to a few days) or do with other
Drying prescription (include silica gel, molecular sieve, phosphorus pentoxide, sodium hydroxide, natrium carbonicum calcinatum, anhydrous calcium chloride, anhydrous
Sodium sulfate, anhydrous magnesium sulfate etc.) environmental condition under or and use the mode of normal pressure or decompression that last product is entered
Row is dried, it is possible to is first processed or the method for distillation band water by the anhydrous benzene mixing placement a few days, and combines described herein
Other drying means obtains after drying so that its moisture is within 0.5%.
The determination of water of the present invention uses Karl_Fischer method, and solvent is methanol, Methanamide, DMF (N, N-dimethyl
Methanamide), one or more in DMSO etc., be more preferably methanol and Methanamide mixed solvent.The Pericarpium Citri junoris of the present invention
The fusing point of glycosides hydrate is measured at different time melting point apparatus, and melting point detector is not corrected.
Powder X-ray diffraction generally can be used to characterize and/or differentiate polymorph, is characterizing for powder X-ray diffraction and/or is differentiating
Time, before report peak value, use modifier " about ".In view of the intrinsic change of peak value, this is the usual of solid-state chemical arts
Way.The usual accuracy of 2 θ x-axle values of coatings spectral peak is in ± 0.2 ° of 2 θ rank, therefore, with " about 8.0 ° of 2 θ
The powder X-ray diffraction maximum occurred means when measuring on most of x-ray diffractometers, and peak may be 7.8 ° of 2 θ and 8.2 °
Between 2 θ.The change of peak intensity is the result how each crystal is orientated relative to external X-ray source in shuttle,
Orientation effect does not provide the structural information about crystal.
The present invention is on the one hand, it is provided that the different crystalline hydrate of Hesperidin and polymorphic.
The present invention is on the one hand, it is provided that the different crystalline hydrate more more stable than Hesperidin anhydride and polymorphic.
The present invention is on the other hand, it is provided that crystalline hydrate that Hesperidin is different and polymorphous preparation method.
The present invention provides a kind of Pharmaceutical composition on the other hand, including any one or more of by the side of the present invention
Hesperidin hydrate prepared by method, and one or more pharmaceutically acceptable excipient.
It is an object of the invention to provide hesperidin crystal hydrate containing dose therapeutically effective as effective ingredient and
The pharmaceutical composition of pharmaceutically acceptable carrier.
The method that the present invention further provides preparation pharmaceutical preparation, including any one or more of by the side of the present invention
Hesperidin hydrate prepared by method and at least one or the merging of pharmaceutically acceptable excipient.
The present invention further provides Hesperidin hydrate, in preparation for treating the reduction blood capillary of people or mammal
Property and the fragility of capillary wall thoroughly, protects blood capillary, prevents the effect that microvascular is hemorrhage;Can be used for multiple
EXUDATIVE DISEASES, as edema, hemorrhage, hypertension, diabetes, chronic venous insufficiency, hemorrhoid, vitamin C deficiency,
Various ulcer and blood vessel contusion etc.;Have simultaneously antiinflammatory, antioxidation, antibacterial, anticancer, regulation immunity, radioprotective,
Protection cardiovascular system, the liver protecting, resisting rheumatoid arthritis or arthritis, antiviral (include herpes simplex
Virus, simplex type I virus, parainfluenza 3 type virus, poliomyelitis I type virus, respiratory tract close spore precursor virus, bleb
Rash I type virus, rotavirus etc. have inhibitory action), antiulcer, eliminate the phlegm, relieving asthma, the regulation of blood pressure and blood lipoid, blood
Pressure regulation, blood circulation be healthy, to Hydroxyl Radical Scavenging and antioxidation, body regulation, treatment black speck,
Purposes in the treatment such as dermatosis aspect effects such as freckle or the food of prevention or health food or pharmaceutical composition.
Hesperidin hydrate of the present invention have for preparation containing Hesperidin through gastrointestinal administration preparation, injection, eye
By the purposes in preparation, external preparation etc., include tablet, capsule, granule, drop pill etc. through gastrointestinal administration;
Injection includes little liquid drugs injection, freeze-dried powder, infusion solutions etc..
The Hesperidin hydrate of the present invention includes tablet, capsule, granule etc. for prepare through gastrointestinal administration;
Tablet (include ordinary tablet, buccal tablet, speed disintegrating tablet, effervescent tablet etc.), capsule (including hard capsule, soft capsule etc.),
Granule, drop pill etc., wherein can contain pharmaceutically acceptable filler, as starch, modified starch, lactose,
Microcrystalline Cellulose, cyclodextrin, sorbitol, mannitol, calcium phosphate, aminoacid etc.;Pharmaceutically acceptable disintegrating agent,
Such as starch, modified starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl
Base cellulose, surfactant (sodium lauryl sulphate etc.);Pharmaceutically acceptable wetting agent and binding agent, such as glue
Change starch, methylcellulose, sodium carboxymethyl cellulose, ethyl cellulose, polyvinylpyrrolidone, alginic acid and
Salt;Pharmaceutically acceptable lubricant and fluidizer, as stearic acid, magnesium stearate, Macrogol 4000-8000,
Pulvis Talci, micropowder silica gel, Stepanol MG etc.;Pharmaceutically acceptable sweeting agent and essence, as aspartame,
Cyclamate, saccharin sodium, sucralose, edible essence etc..
Obtain compositions can prepared, in wet granulation mistake by wet granulation for preparing tablet or hard capsule implant
Cheng Zhong, the excipient of some or all of active component or powder type is mixed, enters one the most again in the presence of liquid
Step mixing, this causes powder grumeleuse to become particle.This particle is sieved and or grind, be dried, then sieve, expire
The granularity hoped, then this particle can make tablet, or add before preparation other excipient, such as fluidizer and/
Or lubricant.
The compositions being prepared as tablet generally can be prepared by being dry mixed.Such as, after active component and excipient mix
Compositions can be compacted into small pieces or thin slice, be then comminuted into the granule of compacting, the granule of this compacting can be with
After be suppressed into tablet.
As the replacement of dry granular method, mixed compositions can obtain evenly with dry method direct compression, direct compression
Tablet.The excipient being particularly suitable for direct compression includes microcrystalline Cellulose, the lactose calcium phosphate of spray drying and colloid two
Silicon oxide.These and other excipient is proper use of in direct compression is to the skill in this area with experience and technical ability
Art personnel are known.
The capsule filling of the present invention can comprise any of above mixture and particle or granule, and it describes with reference to preparation
Piece agent, but they do not carry out the last step being prepared as tablet.
Prepared by drop pill: the product of the present invention of 1 part of weight is dissolved in the melted pharmaceutically acceptable of 1-10 part weight
In substrate, fully stir evenly, in coolant, prepare drop pill, throw away the refrigerant with dropping preparation method, be drying to obtain drop pill.This
The pharmaceutically acceptable substrate of invention includes singly being not limited to poloxamer, glycerin gelatine, polyoxyethylene 40 monostearate
Ester, stearic acid, octadecanol, hexadecanol, glyceryl monostearate, polyethylene glycol 6000, Macrogol 4000 etc.;
Coolant includes but not limited to dimethicone, vegetable oil, liquid paraffin, ethanol, water etc..
The crystalline hydrate of the present invention is different from the deliquescence of anhydride and makes the air to be completely cut off when processing prevent adhesion etc.,
And crystalline hydrate has good sliding, thus improve the operability of preparation;And make the solid preparation of preparation have
There is good dissolving out capability so that it is readily absorbed by entering blood circulation, improve bioavailability, and be conducive to fast
Speed plays its effect.
Dosing eyes preparation or the preparation of ophthalmic preparation
In the preparation of hesperidin crystal hydrate eye drop, the parts by weight of each component can be: hesperidin crystal hydrate
0.1-1, cosolvent 0.1-1, antioxidant 0.02-0.5, metal chelating agent 0.01-0.2, osmotic pressure regulator 0.5-10, anti-
Rotten agent 0.002-0.4, water is 10-200 part, separately adds pH adjusting agent appropriate.
Its preparation method may is that and added in appropriate water for injection by Hesperidin hydrate, adds cosolvent, stirring, examination
Dissolve, add antioxidant, preservative, osmotic pressure regulator, stabilizer, pH adjusting agent, water, stir, Cheng Rong
Aqueous, make pH=7.5~10.0, filter in the mode such as microporous filter membrane or ultrafiltration, detection, aseptic subpackaged in sterilized
In clean plastics eyedrops bottle and get final product.
The injection of Hesperidin hydrate, its preparation method is:
The preparation method of freeze-dried powder is: take Hesperidin hydrate, can add pharmaceutically acceptable lyophilizing support
Agent or auxiliary shape agent, inject with water, add pharmaceutically acceptable soda acid, be stirred to dissolve, and regulation pH is 7.5~10.0,
Adding activated carbon 0.005~0.5% (W/V) and stir 15~45min, filter, moisturizing, aseptic filtration, by 20~600mg
/ bottle (in terms of principal agent) subpackage, lyophilization, tamponade, obtain finished product.
Hesperidin hydrate injection with small volume and preparation technology thereof: Hesperidin hydrate injects with water and pharmaceutically may be used
The additives accepted, such as: pharmaceutically acceptable pH adjusting agent, pharmaceutically acceptable antioxidant, noble gas,
Filtering, degerming make sterilizing injection with small volume, its pH value is between 7.5~10.0.
Pharmaceutically acceptable pH adjusting agent can be pharmaceutically acceptable mineral acid or organic acid, inorganic base or organic
Alkali, it is also possible to be lewis acid or the alkali of broad sense, can be contained one or several, can be hydrochloric acid, phosphoric acid, third
Acid, acetic acid and acetate, such as sodium acetate etc., lactic acid and lactic acid pharmaceutical salts, citric acid pharmaceutical salts, sodium carbonate, carbonic acid
Hydrogen sodium, potassium bicarbonate, sodium hydroxide, phosphate, tartaric acid and pharmaceutical salts thereof, Borax, boric acid, succinic acid, oneself
Acid, adipic acid, fumaric acid, maleic acid, trihydroxy aminomethane, diethanolamine, ethanolamine, isopropyl
Hydramine, diisopropanolamine (DIPA), 2-amino-2-(methylol) 1,3-PD amine, 1,2-hexamethylene diamine, N-methyl glucose amine,
Diisopropylamine and their salt, multi-hydroxy carboxy acid and pharmaceutical salts, as glucuronic acid, gluconic acid, lactobionic acid,
One or several in malic acid, threonic acid THREONIC ACID., glucoheptonic acid, aminoacid and amino acid salts etc..
Pharmaceutically acceptable antioxidant and stabilizer can be sulfurous acid, sulphite, bisulfites, burnt sulfurous
Hydrochlorate, dithionite, thiosulfate, organosulfur compound thiourea, glutathion, dimercaptopropanol, BAL, mercapto
Guanidine-acetic acid and salt, 2-mercaptopropionic acid and pharmaceutical salts thereof, thio-2 acid and salt, phenol or derivatives thereof, such as gallic acid
And pharmaceutical salts, caffeic acid and pharmaceutical salts thereof, ferulic acid and pharmaceutical salts thereof, di-t-butyl Pyrogentisinic Acid, 2,5-dihydroxy
Benzoic acid, DHB salt, salicylic acid or its salt;Aminoacid and its salt;Ascorbic acid and Vitamin C
Hydrochlorate, arabo-ascorbic acid and erythorbate, nicotiamide, tartaric acid, nitrate, phosphate, acetic acid pharmaceutical salts,
Citrate, EDTA and edta salt, such as EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, EDTA tetra-sodium, N-bis-(2
-ethoxy) one or several in glycine etc..
Pharmaceutically acceptable isoosmotic adjusting agent can be glucose, fructose, xylitol, sorbitol, mannitol, turn
Change one or more in sugar, maltose, dextran, sodium chloride, potassium chloride, sodium lactate etc..
Go thermal source and degerming mode can be add dosing amount 0.005~3% activated carbon remove thermal source, microporous filter membrane is degerming
And pressure sterilizing, it would however also be possible to employ heat sterilization, remove thermal source.In hyperfiltration process, ultrafilter can be selected for flat, volume
Formula, tubular type, hollow fiber form or circle boxlike etc., preferably rolling and hollow fiber form ultrafilter, use to retain and relatively divide
Protonatomic mass be 5 ten thousand to 30 ten thousand filter membrane remove major part heat generation material and antibacterial after, then use retain average molecular matter
The ultrafilter membrane of amount 3000~60000 removes residue thermal source, the preferably ultrafilter membrane of relative molecular mass 3000~20000.
Consumption usage: generally, in the adult of 60-70kg body weight, take Hesperidin hydrate 0.020 of the present invention~
The freeze-dried powder of 0.2g or little liquid drugs injection in glucose 20~500 milliliter, are made quiet in 0.9% sodium chloride or 5~10%
Arteries and veins is injected or instils, every day 1~2 times, 0.9% sodium chloride of Hesperidin hydrate or 5~10% glucose
The route of administration of great transfusion preparation is intravenous injection, and dosage is the same;Intramuscular injection: take medicine 0.020 of the present invention~
0.2g freeze-dried powder is dissolved in water for injection, intramuscular injection, every day 1~2 times;Child's amount of halving is used above.
Through gastrointestinal administration dosage, it is generally oral: in the adult of 60-70kg body weight, 25-500mg/ time, 1-3
Times/day, child's amount of halving is used above.
The product of the present invention further provides for the purposes for preparing the chromocor derivative such as hesperidin methyl or diosmin.
The present invention further provides the product of the preparation present invention for preparing Hesperidin hydrate and diosmin or its solvent chemical combination
The purposes of the pharmaceutical composition of one or more compositions in thing or its pharmaceutical salts, wherein, Hesperidin hydrate and buchu
Taking charge of bright or its solvated compounds or its pharmaceutical salts weight ratio is 2:1~1:20, wherein, and Hesperidin hydrate and buchu
Take charge of bright or its solvated compounds or its pharmaceutical salts weight both to calculate according to its crystalline hydrate weight, it is possible to according to
The weight of its anhydride calculates.
The weight ratio of pharmaceutical composition can be: Hesperidin hydrate and diosmin or diosmin hydrate weight ratio
For 1:1~10 (said components all can convert with its hydrate or its hydrate be anhydride calculate two medicines weight or
Weight ratio);Such as, the medicine of 1g compositions or a unit dose can contain diosmin or diosmin hydrate
0.9g, Hesperidin hydrate 0.1g;The medicine of 0.5g compositions or a unit dose can contain diosmin 0.45g,
Hesperidin 0.05g (said components can be all anhydride calculated weight according to hydrate or conversion);Or 0.25g compositions
With in the medicine of a unit dose containing diosmin or diosmin hydrate 0.45g, Hesperidin 0.025g (above-mentioned group
Dividing can be all anhydride calculated weight according to hydrate or conversion);The department Han buchu in the pharmaceutical composition of one unit dose
Bright or diosmin hydrate 0.40g, Hesperidin 0.10g;Or the department Han buchu in the pharmaceutical composition of a unit dose
Bright 0.30g, Hesperidin 0.20g;Or the 0.25g Han diosmin in the pharmaceutical composition of a unit dose, Hesperidin
0.25g;Or the 0.20g Han diosmin in the pharmaceutical composition of a unit dose, Hesperidin 0.40g;Above-mentioned each medicine
Principal agent component in compositions the most all can be converted as anhydride calculated weight with its hydrate or its hydrate;At above-mentioned group
Compound can contain pharmaceutically acceptable adjuvant or excipient.This pharmaceutical composition is mainly used in treating chronic venous
Functional defect, hemorrhoid, hydrarthrosis, venous leg ulcers, premenstrual tension syndrome, the microangiopathy of diabetics
Become and Secondary cases upper limb lymphedema etc..
Code name in the accompanying drawing of the present invention, if any the person of not indicating, can come according to entire content in this specification or performance data
Carry out a volume judgement, determine that it belongs to which embodiment or which compound.If affiliated accompanying drawing diagram data has unintelligible
Place with data in this specification for supplement according to or explanation, or accompanying drawing and description in data complement one another explanation.
If collection of illustrative plates numbering fails clearly etc., to carry out reasoning according to specification and drawings and determine.
Accompanying drawing explanation
Fig. 1 is thermal analysis curue spectrum (embodiment 1) of Hesperidin 0.75 hydrate;
Fig. 2 is the X powder diffraction spectrum data (embodiment 1) of Hesperidin 0.75 hydrate;
Fig. 3 is the X powder diffraction spectrum data (embodiment 1) of Hesperidin 0.75 hydrate;
Fig. 4 is the X powder diffraction collection of illustrative plates (embodiment 1) of Hesperidin 0.75 hydrate;
Fig. 5 is thermal analysis curue spectrum (embodiment 2) of Hesperidin 1 hydrate;
Fig. 6 is the X powder diffraction spectrum data (embodiment 2) of Hesperidin 1 hydrate;
Fig. 7 is the X powder diffraction collection of illustrative plates (embodiment 2) of Hesperidin 1 hydrate;
Fig. 8 is thermal analysis curue spectrum (embodiment 3) of Hesperidin 0.75 hydrate;
Fig. 9 is the X powder diffraction spectrum data (embodiment 3) of Hesperidin 0.75 hydrate;
Figure 10 is the X powder diffraction collection of illustrative plates (embodiment 3) of Hesperidin 0.75 hydrate;
Detailed description of the invention
Except in an embodiment and indicated otherwise time, all of numerical value used in specification and claims should be by
It is interpreted as modifying with term " about " in all of example, therefore, unless the contrary indication, this specification
Being approximation with the numerical parameter gone out given in appending claims, it can be sought according to by present disclosure
The required character asked and change, at least, and be not intended to limit the application of doctrine of equivalents right,
Each numerical parameter is considered as the number of significant digits and the routine method of rounding up is explained.
Although the numerical range and the parameter that set the wide scope of disclosure are approximations.But institute in a particular embodiment
The numerical value be given is reported as precisely as possible, and any number substantially comprises some and sent out by the test of each of which
The error that existing standard deviation is necessarily led to.
It is pointed out that unless literary composition the most additionally illustrates, use in this specification and the appended claims
Singulative " ", " a kind of " and " being somebody's turn to do " include the plural form that refers to thing, so, such as.If
The mixture of two or more compound is included when mentioning the compositions containing " a kind of compound ", also note that
, unless the most additionally illustrated, term "or" generally includes "and/or".
As used herein, term " obtains " referring to the compound of valuable purity level isolated, and described is pure
Degree level includes but not limited to more than 90%, the purity level of 95%, 96%, 97%, 98% and 99%.Described is pure
Degree level can pass through high-performance liquid chromatogram determination.
" pharmaceutical composition " used herein refers to the compositions of medicine, and described pharmaceutical composition can be containing at least one
Plant pharmaceutically acceptable carrier.
" pharmaceutically acceptable excipient " used herein refers to the medicine that the compound being applicable to occasionally provide herein is administered
With carrier or solvent, it includes well known to a person skilled in the art any examples of such carriers being applicable to specific administration mode,
Such as, Sterile dilution can be included for parenteral, intradermal, the subcutaneous or solution of topical application or suspending agent
Agent (such as, water for injection, saline solution, expressed oi etc.);Fatty solvent (such as, the Polyethylene Glycol, sweet of synthesis
Oil, propylene glycol etc.);Antibacterial (such as, benzylalcohol, to hydroxyl the third methyl formate, to hydroxyl the third Ethyl formate etc.);
Antioxidant (such as, ascorbic acid, sodium sulfite etc.);Chelating agen (such as, EDTA etc.);Buffer agent (phosphorus
Hydrochlorate, citrate etc.);With or for tonicity-adjusting substances (e.g., sodium chloride, glucose etc.), or they
Mixture.Other example includes, when intravenous administration, suitable carrier includes normal saline, phosphate-buffered
Liquid and the solution containing thickening agent, such as glucose, Polyethylene Glycol etc. and their mixture.
As non-limiting example, Hesperidin hydrate can optionally and one or more pharmaceutically acceptable excipient
Mixing, and can be with following form oral administration: tablet, capsule, dispersible powder, granule or containing such as
The suspensoid of about 0.05-5% suspending agent or with the form parenteral of sterile solution agent or suspensoid, described suspensoid
Suspending agent in isotonic medium and containing 0.05-5%, these pharmaceutical preparatioies can be containing e.g., from about 25% to about 90%
Active component and carrier, more generally contain the active ingredient of 5% to 60% (weight).
In order to further appreciate that the present invention, below in conjunction with embodiment, the preferred embodiment of the invention is described, but
Should be appreciated that these describe simply for further illustrating the features and advantages of the present invention rather than wanting right of the present invention
The restriction asked, protection scope of the present invention is not limited by the following examples.
Infrared spectrum: pressing potassium bromide troche, measures sample ir data, and the instrument used includes that U.S.'s thermoelectricity is public
Department NICOLET 5700FTIR Spectrometer, Nexus intelligent Fourier transformation infrared spectrometer (Thermo
Nicolet) etc..
Heat analysis method
Hot analytical test strip part: Setaram company Setsys 16, about sample size 3-10mg, programming rate: 10K/min,
N2Flow velocity: 50ml/min, temperature: room temperature~about 400 DEG C.
Surprisingly, distinctive, the heat of the hydrate of the present invention analyzes (TG-DTA or TG-DSC) figure
Having the endothermic peak of correspondence under the weightless platform of spectrum, thermal analysis curue spectrum demonstrates hesperidin crystal hydrate;Karl Fischer
Method test proves that this weightlessness is hydrone.
Powder X-ray diffraction approach
Utilize D/MX-III A X-ray diffractometer, voltage: 30-60kv, electric current: 30-100mA, scanning speed: 10 °/min,
Step-length: 0.02 °/step;Copper target, monochromator: graphite monochromator;WavelengthThe angle of diffraction 2 θ,
Sweep limits 3-60 °, measures the x-ray diffractogram of powder of sample, and whole peak positions are in ± 0.2 ° of 2 θ.Or utilize moral
The D8Advance X-ray diffractometer of Bruker company of state, wavelengthThe angle of diffraction 2 θ, sweep limits 3-60 °,
Other (index such as voltage, electric current) is about the same, measures sample.Each accompanying drawing in this specification and data
Prove each other;The data of the embodiment in the description of the present invention are proved with data each other with each accompanying drawing in description.
Specific embodiment
The preparation of embodiment 1 Hesperidin 0.75 hydrate, in stainless steel cask, adds 2kg dry Pericarpium Citri junoris fine powder, adds
The water of 12 times amount, 1 times amount soak with ethanol after extract 30 points with frequency ultrasonic assistant between 25kHz-50kHz
Clock, adds enough saturated limewaters, stirring, controls about the pH=11.5-12 of solution, and under agitation soaks 2
Hour, filter separating solid substances, obtain the filtrate of Part I filtering residue and Part I;The filtrate of gained Part I is used
The hydrochloric acid solution regulation pH to 4-6 of 3M, places, makes precipitation fully separate out;Gained Part I filtering residue is again with 6 times
The water of amount, the soak with ethanol of 0.1 times amount are also extracted 30 minutes with frequency ultrasonic assistant between 25kHz-50kHz,
Add saturated limewater, stirring, control about pH=11.5, so soak 2 hours, filter, gained Part II
The hydrochloric acid solution of filtrate 2M, regulates pH to 5, places, makes precipitation fully separate out;Sucking filtration, collects Part I
Filtrate and the precipitate of Part II filtrate, be washed to weakly acidic pH, by the sodium hydroxide solution of gained solids 1M
Dissolve, add 15 times amount 50% ethanol water, stirring, place, sucking filtration, gained filtrate add up amount of liquid about 1%
Activated carbon (envelope-bulk to weight ratio=milliliter: gram), stir about 30 minutes, sucking filtration, the hydrochloric acid of gained filtrate 3M
Solution, regulates pH to 5, and 4 DEG C are arranged below, make precipitation fully separate out, and wash gained precipitate to weakly acidic pH with water,
With the abundant rinse of ether and petroleum ether 3 times, sucking filtration, then with the abundant rinse of ethanol 3 times, sucking filtration, gained solid is added
After appropriate organic solvent DMF (DMF) is stirred to dissolve, the work of about the 1% of totalling amount of liquid
Property charcoal (envelope-bulk to weight ratio=milliliter: gram), stir about 30 minutes, cross and filter to remove activated carbon, by gained filtrate water
About 400ml, ethanol about 20ml carries out crystallization operation, places, make precipitation fully separate out between 0~-10 DEG C, sucking filtration,
With washing with alcohol solid 3 times, with isopropanol washing solid 5 times, sucking filtration, by gained solid with appropriate DMF (N,
Dinethylformamide) be stirred to dissolve after, with water about 400ml, acetonitrile about 20ml, isopropanol about 20ml, carry out
Recrystallization operation, sucking filtration, after gained solid is stirred to dissolve with appropriate DMF (DMF),
With water about 400ml, ethanol about 20ml, the most in accordance with the law recrystallization 2 times, place 1 day in 0~about-10 DEG C, make solid
Body fully separates out, sucking filtration, with washing with alcohol solid 3 times, washs solid 3 times, washing 5 times with isopropanol, sucking filtration,
Gained solids is made thinner about 30 DEG C forced air dryings about 4 hours, then is placed in about 71 DEG C and is dried 3 hours, obtains class white
Color powder 6.32g;Fusing point: 258.4~262.2 DEG C, (melting point apparatus does not corrects) is decomposed in variable color;Differentiate: (1) takes this
Bright product about 5mg (calculates quality by anhydride), after adding ethanol 5ml heating for dissolving, lets cool, adds magnesium powder 0.2g, edge
Tube wall is slowly added dropwise hydrochloric acid about 2ml, displaing amaranth.(2) ultraviolet takes product of the present invention (calculating quality by anhydride),
Accurately weighed, add 50% ethanol solution and dissolve and quantitatively dilution makes in every 1ml the solution containing about 20 μ g, according to light splitting light
Degree method (Chinese Pharmacopoeia two annex IV A of version in 2000), measures trap, absorptance at the wavelength of 285nmIn the range of 318~338;ESI-MS:m/z:611 [M+1]+;Infrared spectrum (νKBr max cm-1): 3546.2,
3475.7、3425.7、2979.9、2938.6、2917.3、1648.2、1607.3、1520.1、1467.7、1443.7、
1402.3、1359.5、1300.1、1277.8、1241.5、1205.2、1184.4、1156.1、1132.4、1096.8、
1069.1、1033.1、973.8、891.2、846.8、817.0、767.3;It is 2.32% that Ka Shi method measures moisture, heat point
Analysis collection of illustrative plates: platform weightlessness about 2.18%, this contains the result (theoretical value 2.17%) of 0.75 water of crystallization by mistake with sample
(see accompanying drawing 1) in the range of difference;X-ray powder diffraction spectrum (see accompanying drawing 2,3,4), is including following 2 θ values
Position there is corresponding eigenvalue, be about: 3.84,5.31,7.14,7.81,8.13,8.59,11.40,12.23,
13.27、13.72、15.63、16.04、16.31、17.20、18.31、18.66、19.28、19.67、20.85、21.26、
21.46、22.35、22.62、23.31、23.85、24.02、24.28、24.59、24.92、25.44、25.77、25.90、
26.20、26.63、26.88、27.62、28.07、28.42、28.80、29.23、29.75、30.57、31.20、32.05、
32.94、34.73、35.08、36.19、37.28、38.24、39.68、40.13、40.72、42.79、44.29;Element
Analysis theories value: C 53.89%, H5.73%;Measured value: C 53.78%, H5.65%.
The preparation of embodiment 2 Hesperidin 1 hydrate, in stainless steel cask, adds 3kg dry Pericarpium Citri junoris fine powder, adds 12 times amount
Water soaking 1 hour, add enough saturated limewaters, stirring, control about the pH=11.5-12 of solution, and stirring
Mix lower immersion 2 hours, filter separating solid substances, obtain the filtrate of Part I filtering residue and Part I;Gained Part I
The hydrochloric acid solution regulation pH to 4-6 of filtrate 3M, place, make precipitation fully separate out, obtain the heavy of Part I filtrate
Shallow lake thing;Gained Part I filtering residue with the water soaking of 10 times amount, adds saturated limewater again, stirring, controls pH=11.5 left
The right side, so soaks 2 hours, filters, discards filtering residue, the hydrochloric acid solution regulation pH of the filtrate 3M of gained Part II
To 4.5, place, make precipitation fully separate out, obtain the precipitate of Part II filtrate;Sucking filtration, collects Part I respectively
The precipitate of filtrate and the precipitate of Part II filtrate, be washed to weakly acidic pH, then will extract two parts of gained
Solids merging is placed in flask, adds the water of 3 times of volumes, and makes it dissolve with the sodium hydroxide solution of 1M, adds 12 times
The ethanol water of the 51% of amount, stirring, to place, sucking filtration, gained filtrate adds up the activated carbon (volume of about the 1% of amount of liquid
Weight ratio=milliliter: gram), stir about 30 minutes, sucking filtration, the hydrochloric acid solution regulation pH to 5-6 of gained filtrate 3M,
4 DEG C are arranged below, make precipitation fully separate out, and wash gained precipitate to weakly acidic pH with water, then with the abundant rinse of ethanol 2
Secondary, with the abundant rinse of ether and hexamethylene 3 times, sucking filtration, the abundant rinse of methanol 2 times, with the abundant rinse of acetone 1 time, take out
Filter, adds gained solid after appropriate organic solvent DMF (DMF) is stirred to dissolve, adds up
The activated carbon of amount of liquid about 1% (envelope-bulk to weight ratio=milliliter: gram), stir about 30 minutes, cross and filter to remove activated carbon,
Gained filtrate is carried out crystallization operation with ethanol about 20ml, acetonitrile about 10ml, acetone about 10ml, water about 400ml, in 0~
Placing between-10 DEG C, make precipitation fully separate out, sucking filtration, gained solid washing with alcohol solid 2 times, isopropanol is abundant
Rinse 2 times, with the abundant rinse of acetone 2 times, sucking filtration, by gained solid with appropriate DMF (N, N-dimethyl formyl
Amine) be stirred to dissolve after, with ethanol about 20ml, acetone about 20ml, water about 400ml, carry out recrystallization operation, as
These recrystallization three times the most again, place 2 days in 0~about-10 DEG C, make solid fully separate out, and sucking filtration uses washing with alcohol
Solid 2 times, sucking filtration;Again with water abundant rinse solid, sucking filtration, such 8 times;Gained solids is made thinner about 30 DEG C drums
Air-dry dry about 6 hours, then be placed in 50 DEG C dry 4 hours, obtain off-white powder 7.26g;Fusing point: 258.2~261.7 DEG C,
(melting point apparatus does not corrects) is decomposed in variable color;Differentiate: (1) takes product of the present invention about 5mg (calculating quality by anhydride), adds
After ethanol 5ml heating for dissolving, let cool, add magnesium powder 0.2g, be slowly added dropwise hydrochloric acid about 2ml, displaing amaranth along tube wall.(2)
Ultraviolet takes product of the present invention (calculating quality by anhydride), accurately weighed, adds 50% ethanol solution and dissolves and the dilutest
Release the solution made in every 1ml containing about 20 μ g, according to spectrophotography (Chinese Pharmacopoeia two annex IV A of version in 2000),
Trap, absorptance is measured at the wavelength of 285nmIn the range of 318~338;ESI-MS:m/z:
611[M+1]+;Infrared spectrum (νKBr max cm-1): 3546.6,3474.8,3425,3081.7,2980.2,2938.8,
2916.9、1647.9、1607.4、1519.9、1467.3、1443.6、1402.2、1359、1299.7、1277.8、1241、
1204.9、1184.2、1156、1132.2、1096.6、1068.6、1032.8、973.6、911.2、891.2、846.5、
816.5、767.2;It is 3.01% that Ka Shi method measures moisture, and heat analyzes TG-DTA: platform weightlessness about 2.85%, this and sample
Product contain the result (theoretical value 2.87%) of 1 water of crystallization in range of error (see accompanying drawing 5);X-ray powder diffraction
5.27,7.12 collection of illustrative plates (see accompanying drawing 6, accompanying drawing 7), has corresponding eigenvalue in the position including following 2 θ values, is about:,
7.78、8.11、8.56、11.39、12.23、13.24、13.70、15.61、15.88、16.29、17.18、18.29、
18.66、19.67、20.82、21.23、21.42、21.73、22.33、22.60、23.30、23.81、24.29、24.55、
24.91、25.44、25.89、26.18、26.59、26.88、27.62、28.47、28.77、29.18、29.72、30.55、
31.15、32.05、32.92、34.69、35.06、36.19、37.28、38.19、38.51、39.63、40.21、44.04、
46.42、47.58;Elementary analysis, theoretical value: C 53.50%, H5.77%;Measured value: C 53.57%, H5.68%.
The preparation of embodiment 3 Hesperidin 0.75 hydrate, in stainless steel cask, adds 2.2kg dry Pericarpium Citri junoris fine powder, adds 8 times
The ethanol of amount, the water of 3 times amount, use frequency ultrasonic assistant between 25kHz-50kHz to extract 30 after soaking 3 hours
Minute, filtering, the filtrate of Part I and part 1 filtering residue, filtering residue adds the water soaking 1 hour of 12 times amount, adds
Saturated limewater, stirring, control about the pH=11.0-12 of solution, and under agitation soak 2 hours, filter separation solid
Body thing, obtains the filtrate of part 2 filtering residue and Part II;The filtrate of gained Part I and the filtrate of Part II are used
The hydrochloric acid solution regulation pH to 4-6 of 2M, places, makes precipitation fully separate out, and sucking filtration, gained solid is solid by washing with alcohol
Body 3 times, with the abundant rinse of acetone 2 times, sucking filtration, is washed to weakly acidic pH, sucking filtration, obtains the first and second portion filtrate
Precipitate;Gained Part II filtering residue with the water soaking of 6 times amount, adds saturated limewater again, stirring, controls pH=11.5
Left and right, so soaks 2 hours, filters, discards filtering residue, the hydrochloric acid solution regulation of the filtrate 3M of gained Part III
PH to 5, places, makes precipitation fully separate out, sucking filtration, gained solid washing with alcohol solid 3 times, fully moistens with acetone
Wash 2 times, sucking filtration, be washed to weakly acidic pH, sucking filtration, obtain the precipitate of Part III filtrate;Part I will be collected respectively
Merging with the precipitate of Part II filtrate and the precipitate of Part III filtrate and be placed in flask, the water adding 8 times amount stirs
Mixing about 1 hour, add saturated limewater, regulate pH=10-11.5, stirring, filter, filtrate adds the hydrochloric acid solution of 2M,
Regulation pH to 3, places, makes precipitation fully separate out, and filters, gained solid washing with alcohol solid 3 times, uses second respectively
The abundant rinse of ether, ethyl acetate, petroleum ether, chloroform 1 time, sucking filtration, with the abundant rinse of acetone 2 times, sucking filtration, by institute
Solid adds appropriate DMF and DMSO, after heated and stirred makes dissolving, add proper amount of active carbon, stir about 30 minutes,
Filter, gained filtrate water about 60ml, isopropanol about 30ml, acetone about 30ml are carried out crystallization operation, in 0~-10 DEG C
Left and right is placed 2 days, makes solid fully separate out, and filters to obtain solid washing with alcohol solid 3 times, with the abundant rinse of acetone 2 times,
Wash 3 times, sucking filtration, by gained solid DMF about 100ml, water about 500ml, isopropanol about 30ml, heavily tie
Crystalline substance, and so recrystallization three times in accordance with the law, place and make solid fully separate out, sucking filtration, gained solid washing with alcohol solid 3
Secondary, with the abundant rinse of acetone 2 times, sucking filtration, wash 3 times, sucking filtration, so recrystallization 2 times the most again of gained solid,
Place 2 days in 0~about-10 DEG C, make solid fully separate out, sucking filtration, filter to obtain solid washing with alcohol solid 3 times,
With the abundant rinse of acetone 2 times, washing 3 times, sucking filtration, gained solids is made thinner about 25 DEG C and is dried about 1 day, then 40 DEG C
Left and right vacuum (the vacuum meter reading of vacuum drying oven is about about 0.08MPa) be dried 2 hours, then be placed in 70 DEG C do
Dry 2 hours, obtain class color powder 7.58g;Fusing point: 258.4~261.6 DEG C, (melting point apparatus does not corrects) is decomposed in variable color;Differentiate:
(1) take product of the present invention about 5mg (calculating quality by anhydride), after adding ethanol 5ml heating for dissolving, let cool, add magnesium
Powder 0.2g, is slowly added dropwise hydrochloric acid about 2ml, displaing amaranth along tube wall.(2) ultraviolet takes product of the present invention (by anhydride
Calculate quality), accurately weighed, add 50% ethanol solution and dissolve and quantitatively the solution containing about 20 μ g is made in every 1ml in dilution,
According to spectrophotography (Chinese Pharmacopoeia two annex IV A of version in 2000), at the wavelength of 285nm, measure trap, inhale
Receive coefficientIn the range of 318~338;Infrared spectrum (νKBr max cm-1): 3545.0,3476.3,3423.2,
2938.0、2917.7、2850.4、1648.1、1607.1、1519.9、1467.3、1443.6、1402.1、1359.8、
1300.2、1277.5、1241.7、1205.2、1184.2、1155.9、1132.3、1096.7、1069.2、1033.0、
972.9、877.8、846.8、817.2、767、743;It is 2.35% that Ka Shi method measures moisture, heat analysis TG-DTA:
Platform weightlessness about 2.10% (see accompanying drawing 8), this result (theoretical value 2.17%) containing 0.75 water of crystallization with sample exists
In range of error;Elementary analysis, theoretical value: C 53.50%, H5.77%;Measured value: C 53.59%, H5.71%;
Powder X-ray diffraction (see accompanying drawing 9,10), has corresponding eigenvalue in the position including following 2 θ values, is about:
5.29、7.13、7.78、8.11、8.55、11.39、12.21、13.24、13.69、15.59、16.00、16.29、17.16、
18.31、18.62、19.65、20.82、21.21、21.42、22.31、22.59、23.30、23.81、24.29、24.55、
24.88、25.41、25.87、26.16、26.61、26.86、27.72、28.42、28.78、29.72、30.54、31.12、
32.03、32.96、34.72、35.06、36.24、37.29、38.21。
The preparation of embodiment 4 freeze-dried powder takes Hesperidin hydrate 10g (preparation of embodiment 1 method or embodiment 2 method
Or embodiment 3 method), add xylitol 2.0~5g and add fresh water for injection 500ml stirring, by phosphoric acid and the hydroxide of 1M
Sodium solution regulation pH is 8.5~10.0, makes to be dissolved into solution, adds activated carbon 0.01~0.5% (W/V) and stir 15~45min,
Filter, moisturizing to 600ml, with 0.22 micrometer Millipore membrane filtration, by 50mg/ bottle, 100mg/ bottle or 200mg/ bottle (with
Principal agent anhydride meter) subpackage, lyophilization, tamponade, obtain finished product.
The preparation of embodiment 5 injection takes Hesperidin hydrate 10g (by the preparation of embodiment 1 method or embodiment 2 method or reality
Execute example 3 method to prepare), with mannitol 40g, add 40-60 DEG C of water for injection 500ml stirring, by citric acid and the hydroxide of 1M
Sodium regulation pH is 8.0~9.5, makes to be dissolved into solution, adds activated carbon 0.01~0.5% (W/V) and stir 15~45min, mistake
Filter, moisturizing to 600ml, retain relative molecular mass 6000-20000's with 0.22 micrometer Millipore membrane filtration or employing
Ultrafiltration membrance filter, by 50,100mg/ bottle or 200mg/ bottle (by Hesperidin 1 hydrated basis) subpackage, lyophilization, pressure
Plug, obtains finished product.
The Hesperidin hydrate 10.2g for preparing of the little hydro-acupuncture preparation of embodiment 6 (is prepared or embodiment 2 method by embodiment 1 method
Or prepared by embodiment 3 method), add L-arginine 0.8g, EDETATE SODIUM 0.1g, inject and stir with water 400ml, 2M breast
Acid sodium regulation pH is 7.5~9.0, adds activated carbon 0.01% (W/V) and stirs 15~45min, filters, moisturizing to 500ml,
With 0.22 micrometer Millipore membrane filtration, by 5ml/ bottle subpackage, sterilizing obtains finished product.
Embodiment 7 Hesperidin 1 hydrate 10g (is prepared by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method), adds
Water for injection 400ml stirs, and sodium hydroxide solution and sodium dihydrogen phosphate regulation pH with 1M are 7.6~9.0, make molten
Solution becomes solution, adds activated carbon 0.01% (W/V) and stirs 15~45min, filters, moisturizing to 500ml, micro-with 0.22 micron
Hole membrane filtration or employing retain the ultrafiltration membrance filter of relative molecular mass 6000-10000, by 5ml/ bottle subpackage, freezing
It is dried, tamponade, obtains finished product.
The preparation of embodiment 8 Hesperidin hydrate sodium chloride transfusion: (prepared by embodiment 1 method by Hesperidin hydrate 10g
Or embodiment 2 method or embodiment 3 method), sodium chloride 85g, sodium tartrate 1.1g, EDETATE SODIUM 0.2g, add injection
In water, stirring, with the liquor sodii citratis regulation pH value of 2M in the range of 7.2-8.5, make dissolving, inject and use water
To 10000ml, add the activated carbon of dosing amount 0.05%, about heated and stirred 10-30 minute, filtering decarbonization, then warp
0.22um microporous filter membrane fine straining, embedding in the infusion bottle of 50ml or 100ml, sterilizing, pack and get final product.
Embodiment 9 Hesperidin 0.75 hydrate tablet (25mg/ sheet)
The Hesperidin hydrate (preparing by embodiment 1 method) of recipe quantity, microcrystalline Cellulose, carboxymethyl starch sodium are crossed 100
Mesh sieve, PVP K-30 ethanol water (ethanol: the volume ratio=8:2 of water) the solution soft material the most processed with 10%, cross 18
-24 mesh sieves are pelletized, and are dried, and cross after 14-20 mesh sieve granulate, add micropowder silica gel mixing, tabletting, check, pack.
Embodiment 10 Hesperidin hydrate tablet (50mg/ sheet)
The Hesperidin hydrate (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, microcrystalline Cellulose, carboxymethyl are formed sediment
Powder sodium crosses 100 mesh sieves, and PVP K-30 ethanol water (ethanol: the volume ratio=8:2 of the water) solution with 10% is made in right amount
Soft material, crosses 18-24 mesh sieve and pelletizes, be dried, after crossing 14-20 mesh sieve granulate, add micropowder silica gel mixing, tabletting, inspection
Test, pack.
Embodiment 11 Hesperidin hydrate tablet (200mg/ sheet)
The Hesperidin hydrate (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, microcrystalline Cellulose, carboxymethyl are formed sediment
Powder sodium crosses 100 mesh sieves, and PVP K-30 ethanol water (ethanol: the volume ratio=8:2 of the water) solution with 10% is made in right amount
Soft material, crosses 18-24 mesh sieve and pelletizes, be dried, after crossing 14-20 mesh sieve granulate, add micropowder silica gel mixing, tabletting, inspection
Test, pack.
Embodiment 12 Hesperidin hydrate capsule (100mg/ grain)
By the Hesperidin hydrate of recipe quantity (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method), micro-
Crystalline cellulose, starch cross 100 mesh sieves, the gelling starch soft material the most processed with 10%, cross 18-24 mesh sieve and pelletize, are dried,
After crossing 14-20 mesh sieve granulate, add magnesium stearate mixing, fill capsule.
Embodiment 13 Hesperidin hydrate capsule (200mg/ grain)
By the Hesperidin hydrate of recipe quantity (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method), micro-
100 mesh sieves crossed by crystalline cellulose, lactose, the gelling starch soft material the most processed with 10%, cross 18-24 mesh sieve and pelletize, are dried,
After crossing 14-20 mesh sieve granulate, add magnesium stearate mixing, fill capsule.
The granule (100mg/ bag) of embodiment 14 Hesperidin hydrate
By the Hesperidin hydrate (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method) of recipe quantity, manna
Alcohol, lactose, cyclamate, edible essence cross 100 mesh sieves, with the PVP K-30 ethanol water soft material the most processed of 8%,
Crossing 18-24 mesh sieve to pelletize, less than 60 DEG C are dried, and add the xanthan gum of 100 mesh sieves, after crossing 14-20 mesh sieve granulate, mixed
Even, added the xanthan gum of 100 mesh sieves, subpackage fills.
The eye drop of embodiment 15 Hesperidin hydrate
By the Hesperidin hydrate 1g (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, inject and use water 400ml,
Glycerol adding 10ml, PVP K-30 0.5g, add sodium sulfite 0.6g, EDETATE SODIUM 0.3g, Borax 2.5g, chlorination
Sodium 3.1g, is adjusted to 7.1-8.0 with dibastic sodium phosphate and disodium phosphate soln, is stirred to dissolve, and then adds people's water for injection extremely
500ml, stirs, detection, with 0.22-0.45 μm filtering with microporous membrane to clear and bright, is sub-packed in sterilized clean eye
In liquid medicine bottle, sterilizing, let cool, to obtain final product.
Embodiment 16 Hesperidin hydrate and the pharmaceutical composition of diosmin (50mg/450mg/ sheet)
By the Hesperidin hydrate (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, diosmin, microcrystalline Cellulose,
Carboxymethyl starch sodium crosses 100 mesh sieves, with the gelling starch solution soft material the most processed of 10%, crosses 18-24 mesh sieve and pelletizes, dry
Dry, cross after 14-20 mesh sieve granulate, added the magnesium stearate mixing of 100 mesh sieves, tabletting, and checked, pack.
Embodiment 17 Hesperidin hydrate and diosmin (25mg/225mg/ sheet, by anhydride calculated weight) group
The preparation of compound
By the Hesperidin hydrate (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, diosmin, microcrystalline Cellulose,
Carboxymethyl starch sodium crosses 100 mesh sieves, with the gelling starch solution soft material the most processed of 10%, crosses 18-24 mesh sieve and pelletizes, dry
Dry, cross after 14-20 mesh sieve granulate, added the magnesium stearate mixing of 100 mesh sieves, tabletting, and checked, pack.
Embodiment 18 pharmaceutical composition prepare Hesperidin hydrate and diosmin (100mg/400mg/ sheet)
By the Hesperidin hydrate (preparing by embodiment 1 method or embodiment 2 method) of recipe quantity, diosmin, microcrystalline Cellulose,
Carboxymethyl starch sodium crosses 100 mesh sieves, with 10% PVP K-30 ethanol water (8:2) solution soft material the most processed, crosses 18-
24 mesh sieves are pelletized, and are dried, and cross after 14-20 mesh sieve granulate, added the magnesium stearate mixing of 100 mesh sieves, tabletting, inspection,
Packaging.
(50mg/450mg/ sheet, by nothing with diosmin for the Hesperidin hydrate of preparing of embodiment 19 pharmaceutical composition
Water thing calculates the weight of principal agent-Hesperidin and diosmin)
By the Hesperidin hydrate of recipe quantity (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method),
Ao Siming, microcrystalline Cellulose, carboxymethyl starch sodium cross 100 mesh sieves, with the gelling starch solution soft material the most processed of 10%,
Cross 18-24 mesh sieve to pelletize, be dried, cross after 14-20 mesh sieve granulate, added the magnesium stearate mixing of 100 mesh sieves, tabletting,
Inspection, packaging.
The preparation (10000) of embodiment 20 Hesperidin hydrate drop pill
Prescription: Hesperidin hydrate 25g
Poloxamer 20g
Polyethylene glycol 6000 60g
The Hesperidin hydrate (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method) of recipe quantity is crossed 100
After mesh sieve, in the poloxamer that is added to melt, polyethylene glycol 6000 substrate, fully stir evenly, be cold with dimethicone
But agent, dropping preparation method pill, it is dried, packaging.
(50mg/450mg/ bag is calculated by anhydride in the preparation (1000) of the drop pill of embodiment 21 pharmaceutical composition
Principal agent-Hesperidin and the weight of diosmin)
By the Hesperidin hydrate of recipe quantity (preparing by the preparation of embodiment 1 method or embodiment 2 method or embodiment 3 method),
After diosmin crosses 100 mesh sieves, in the poloxamer that is added to melt, polyethylene glycol 6000 substrate, fully stir evenly, with two
Methyl-silicone oil is coolant, dropping preparation method pill, is dried, packaging.
Industrial applicibility etc. and explanation etc. thereof:
Above by detailed description of the invention and embodiment, the present invention is described in detail, it will nevertheless be understood that these are said
Bright to the scope of the present invention any restriction of composition, in the case of without departing from the spirit and scope of protection of the present invention,
Technical solutions and their implementation methods of the present invention can be carried out multiple modification, improve and replace or suitably change and combine,
Realizing the technology of the present invention, these are all because falling within the scope of protection of the present invention;It is appreciated that the change of a lot of details
Being possible, this is also not so limited the scope of the invention, spirit and content, and the present invention is not limited to above-described embodiment.
Claims (13)
1. a flavone compound entity, it is characterised in that: for hesperidin crystal hydrate, molecular formula is C28H34O15·nH2O, n=0.75,1.0.
Flavone compound entity the most according to claim 1, it is characterised in that: for Hesperidin 1 hydrate.
nullFlavone compound entity the most according to claim 2,It is characterized in that: utilize powder X-ray diffractometry to measure,At the angle of diffraction 2 θ、In the range of the measurement of 3-60 °,There is corresponding eigenvalue in the position of following 2 θ values: 5.27、7.12、7.78、8.11、8.56、11.39、12.23、13.24、13.70、15.61、15.88、16.29、17.18、18.29、18.66、19.67、20.82、21.23、21.42、21.73、22.33、22.60、23.30、23.81、24.29、24.55、24.91、25.44、25.89、26.18、26.59、26.88、27.62、28.47、28.77、29.18、29.72、30.55、31.15、32.05、32.92、34.69、35.06、36.19、37.28、38.19、38.51、39.63、40.21、44.04、46.42、47.58.
Flavone compound entity the most according to claim 1, it is characterised in that: for Hesperidin 0.75 hydrate.
nullFlavone compound entity the most according to claim 4,It is characterized in that: utilize powder X-ray diffractometry to measure,At the angle of diffraction 2 θ、In the range of the measurement of 3-60 °,There is corresponding eigenvalue in the position of following 2 θ values: 3.84、5.31、7.14、7.81、8.13、8.59、11.40、12.23、13.27、13.72、15.63、16.04、16.31、17.20、18.31、18.66、19.28、19.67、20.85、21.26、21.46、22.35、22.62、23.31、23.85、24.02、24.28、24.59、24.92、25.44、25.77、25.90、26.20、26.63、26.88、27.62、28.07、28.42、28.80、29.23、29.75、30.57、31.20、32.05、32.94、34.73、35.08、36.19、37.28、38.24、39.68、40.13、40.72、42.79、44.29.
nullFlavone compound entity the most according to claim 4,It is characterized in that: utilize powder X-ray diffractometry to measure,At the angle of diffraction 2 θ、In the range of the measurement of 3-60 °,There is corresponding eigenvalue in the position of following 2 θ values: 5.29、7.13、7.78、8.11、8.55、11.39、12.21、13.24、13.69、15.59、16.00、16.29、17.16、18.31、18.62、19.65、20.82、21.21、21.42、22.31、22.59、23.30、23.81、24.29、24.55、24.88、25.41、25.87、26.16、26.61、26.86、27.72、28.42、28.78、29.72、30.54、31.12、32.03、32.96、34.72、35.06、36.24、37.29、38.21.
7. according to the flavone compound entity described in claim 1-5, it is characterised in that: there is under the weightless platform of 50~130 DEG C of heat analysis TG-DTA collection of illustrative plates the endothermic peak of correspondence.
8. according to the purposes of the flavone compound entity described in claim 1-5, it is characterized in that: the compositions containing this chemical entities for preparation for preparation, this pharmaceutical composition shows as solid preparation, preparation for external application to skin, suppository, injection, solid preparation selected from tablet, capsule, granule or dry suspension.
Flavone compound entity the most according to claim 1, it is characterized in that: the pharmaceutical composition containing this chemical entities for preparation, this pharmaceutical composition is the pharmaceutical composition of Hesperidin hydrate and one or more compositions in diosmin or its solvated compounds or its pharmaceutical salts, wherein, Hesperidin hydrate is 2:1~1:20 with the weight ratio of diosmin or its solvated compounds or its pharmaceutical salts, wherein, the weight of Hesperidin hydrate and diosmin or its solvated compounds or its pharmaceutical salts both can calculate according to its crystalline hydrate weight, also can calculate according to the weight of its anhydride.
The pharmaceutical composition of flavone compound entity the most according to claim 7, it is characterized in that: in the pharmaceutical composition containing this chemical entities, Hesperidin hydrate is 1:1~1:10 with the weight ratio of diosmin or its solvated compounds or its pharmaceutical salts, wherein, the weight of Hesperidin hydrate and diosmin or its solvated compounds or its pharmaceutical salts both can calculate according to its crystalline hydrate weight, it is possible to calculates according to the weight of its anhydride.
Pharmaceutical composition any one of 11. claim 7-9, it comprises the compound any one of claim 1-5, and the weight of described compound is 5-500mg.
12. according to the purposes of the flavone compound entity described in claim 1-5, it is characterized in that preparation reduces the fragility of capillary tube, protection blood capillary, prevent microvascular hemorrhage, chronic venous insufficiency, hemorrhoid, vitamin C deficiency, hydrarthrosis, venous leg ulcers, premenstrual tension syndrome, the microangiopathies of diabetics and Secondary cases upper limb lymphedema, cardiovascular disease, blood pressure and blood lipoid regulates, blood pressure regulating, anti-inflammation, antiviral, anticancer, regulation immunity, radioprotective, the liver protecting, resisting rheumatoid arthritis or arthritis, antiulcer, eliminate the phlegm, relieving asthma, black speck, passeris montani saturati speckle, free radical resisting, application in antioxidative treatment or the food of prevention or health food or medicine.
13. flavone compound entities according to claim 1, its preparation method, it is characterised in that: its preparation method is selected from:
Method A., in reaction vessel, adds the dry Pericarpium Citri junoris powder of the pulverizing of constant weight, adds the water of 3-60 times amount, C1-C6Low mass molecule alcohol, one or more in acetone are soaked and by ultrasonic extraction or microwave extraction 0.1-2 hour, wherein, w/v=gram: milliliter;Then one or more in saturated limewater, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are added, stirring, control pH and be about 9-13, extract or microwave extraction 0.1-3 hour in so soaking and with ultrasonic assistant, filter separating solid substances, obtain filtrate and the Part I filtering residue of Part I;The filtrate diluted mineral acid of gained Part I or organic acid soln regulation pH to 4~7, place, make precipitation fully separate out, filter, the precipitate of Part I filtrate;Gained Part I filtering residue is again with the water of 2-30 times amount, C1-C6Low mass molecule alcohol, one or more in acetone soak ultrasonic extraction or microwave extraction 0.1-2 hour, then one or more in saturated limewater, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are added, stirring, control pH and be about 9-13, so soak and by ultrasonic extraction or microwave extraction 0.1-2 hour, filter, the filtrate mineral acid of gained Part II or organic acid soln regulation pH to 4~7, place, make precipitation fully separate out;Filter, obtain the precipitate of Part II filtrate;Collect Part I filtrate and the precipitate of Part II filtrate, be washed to weakly acidic pH, obtain wet solids;
One or more in gained solids saturated limewater solution, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are dissolved, adds the 20 of 2-40 times amount~the C of 60%1-C6Low mass molecule alcohol, acetone or water, stirring, place, filter, gained filtrate diluted mineral acid or organic acid soln regulation pH to 4~7,25 DEG C are arranged below, make precipitation fully separate out, and wash gained precipitate to weakly acidic pH with water, then use C1-C6Low mass molecule alcohol, C2-C8Low molecule ether, C3-C8Low molecule ketone, C2-C8Low molecule ester, C4-C10Low molecule alkane or cycloalkane, petroleum ether in one or more abundant rinses 1~6 times, filter, gained solid is added appropriate organic solvent Methanamide, N, in dinethylformamide one or more, after being stirred to dissolve, add proper amount of active carbon, stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water, C1-C6Low mass molecule alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out crystallization operation, 20~about-25 DEG C placements, make precipitation fully separate out, filter, with water, C1-C6Low mass molecule alcohol washing solid 1-8 time, sucking filtration, by gained solid appropriate Methanamide, N, in dinethylformamide, DMSO, one or more, after being stirred to dissolve, add proper amount of active carbon, stir about 15-60 minute, crosses and filters to remove activated carbon, by gained filtrate water, C1-C6Low mass molecule alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out recrystallization operation, one or many recrystallization operation, 20~about-25 DEG C placements can be carried out the most in accordance with the law further, make solid fully separate out, filter, with water, C1-C6Low mass molecule alcohol, C3-C8Low molecule ketone washing solid 1-8 time, filtration, gained solids is dried, obtains hesperidin crystal hydrate;Wherein, frequency during supersound extraction is between 10kHz-2000kHz, and the power of microwave extraction is between 100W-1000W;
Or method B. is in reaction vessel, add the dry Pericarpium Citri junoris powder of the pulverizing of constant weight, add the water of 3-60 times amount, C1-C6Low mass molecule alcohol soak extraction 0.5-4 hour, wherein, w/v=gram: milliliter;Then one or more in saturated limewater, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are added, stirring, control pH=10-13, so soak extraction 1-4 hour, filter separating solid substances, the filtrate diluted mineral acid of gained Part I or organic acid soln regulation pH to 4~7, place, make precipitation fully separate out;Gained Part I filtering residue extracts with the water soaking of 2-30 times amount again, then one or more in saturated limewater, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are added, stirring, control pH=10-13, such soak extraction 1-4 hour, filter, the filtrate of gained Part II is with mineral acid or organic acid solns such as dilute hydrochloric acid, sulphuric acid, phosphoric acid, regulation pH to 4~7, places, makes precipitation fully separate out;Filter, collect Part I filtrate and the precipitate of Part II filtrate, be washed to weakly acidic pH, obtain wet solids;
One or more in gained solids use, saturated limewater solution, sodium hydroxide solution, potassium hydroxide solution, sodium carbonate liquor are dissolved, adds the 20 of 2-60 times amount~the C of 60%1-C6Low mass molecule alcohol, acetone or water, stirring, places, and filters, gained filtrate adds up the activated carbon (envelope-bulk to weight ratio=milliliter: gram) of the about 0.01-3% of amount of liquid, stir about 10-60 minute, sucking filtration, gained filtrate diluted mineral acid or organic acid soln regulation pH to 4~7,25 DEG C arranged below, make precipitation fully separate out, gained precipitate is washed with water to weakly acidic pH, then uses C1-C6Low mass molecule alcohol, C2-C8Low molecule ether, C3-C8Low molecule ketone, C2-C8Low molecule ester, C4-C10Low molecule alkane or cycloalkane, petroleum ether in one or more abundant rinses 1~6 times, filter, gained solid is added one or more in appropriate organic solvent dimethyl sulfoxide, Methanamide, DMF, after being stirred to dissolve, add the activated carbon of the about 0.01-3% of total amount of liquid, wherein, the weight of activated carbon and liquor capacity than=gram: milliliter, stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water, C1-C6Low mass molecule alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out crystallization operation, 20~about-25 DEG C placements, make precipitation fully separate out, filter, with water, C1-C6Low mass molecule alcohol washing solid 1-8 time, filter, by gained solid with in appropriate DMSO, Methanamide, DMF (DMF) one or more, after being stirred to dissolve, add the activated carbon of the about 0.01-3% of total amount of liquid, wherein, envelope-bulk to weight ratio=milliliter: gram, stir about 15-60 minute, cross and filter to remove activated carbon, by gained filtrate water, C1-C6Low mass molecule alcohol, C2-C6Rudimentary nitrile, C3-C8Low molecule ketone in one or more carry out recrystallization operation, one or many recrystallization operation can be carried out the most in accordance with the law further, in 20~about-25 DEG C placements, be preferable over 10~about-10 DEG C placements, make solid fully separate out, filter, with water, C1-C6Low mass molecule alcohol, C3-C8Low molecule ketone in one or more washing solids 1-10 time, filtration, gained solids is dried, obtains hesperidin crystal hydrate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510024470.6A CN105837646A (en) | 2015-01-16 | 2015-01-16 | Flavonoid new chemical entity, composition and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510024470.6A CN105837646A (en) | 2015-01-16 | 2015-01-16 | Flavonoid new chemical entity, composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105837646A true CN105837646A (en) | 2016-08-10 |
Family
ID=56580221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510024470.6A Pending CN105837646A (en) | 2015-01-16 | 2015-01-16 | Flavonoid new chemical entity, composition and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105837646A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018010170A1 (en) * | 2016-07-15 | 2018-01-18 | 刘力 | Novel embodiment of flavonoid, and composition and application thereof |
CN108042557A (en) * | 2017-12-07 | 2018-05-18 | 珠海霍普金斯医药研究院股份有限公司 | Aurantiamarin is preparing the application in treating diabetic gangrene drug |
CN109549947A (en) * | 2019-01-25 | 2019-04-02 | 广州中健健康科技有限公司 | A kind of eye spray of anti-blue light and preparation method thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704867A (en) * | 2009-11-03 | 2010-05-12 | 国家***第三海洋研究所 | Method for preparing naringin or hesperidin |
CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
CN102311468A (en) * | 2011-09-09 | 2012-01-11 | 四川天予植物药业有限公司 | Clean production method of hesperidin |
CN102432575A (en) * | 2012-01-19 | 2012-05-02 | 西安小草植物科技有限责任公司 | Method for extracting high-purity hesperetin from immature bitter orange |
CN102839053A (en) * | 2012-08-23 | 2012-12-26 | 高伟 | Method for extracting aurantiamarin from orange peel |
CN103467546A (en) * | 2013-09-16 | 2013-12-25 | 成都欧康医药有限公司 | Production process of hesperidin |
CN103601775A (en) * | 2013-11-27 | 2014-02-26 | 桂林益元素生物科技有限公司 | Method for extracting hesperidin from orange peels |
CN104119411A (en) * | 2014-08-12 | 2014-10-29 | 四川天予植物药业有限公司 | Method for preparing high-purity hesperidin |
CN104262430A (en) * | 2014-09-24 | 2015-01-07 | 王红莲 | Method for extracting aurantiamarin from immature bitter orange |
-
2015
- 2015-01-16 CN CN201510024470.6A patent/CN105837646A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704867A (en) * | 2009-11-03 | 2010-05-12 | 国家***第三海洋研究所 | Method for preparing naringin or hesperidin |
CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
CN102311468A (en) * | 2011-09-09 | 2012-01-11 | 四川天予植物药业有限公司 | Clean production method of hesperidin |
CN102432575A (en) * | 2012-01-19 | 2012-05-02 | 西安小草植物科技有限责任公司 | Method for extracting high-purity hesperetin from immature bitter orange |
CN102839053A (en) * | 2012-08-23 | 2012-12-26 | 高伟 | Method for extracting aurantiamarin from orange peel |
CN103467546A (en) * | 2013-09-16 | 2013-12-25 | 成都欧康医药有限公司 | Production process of hesperidin |
CN103601775A (en) * | 2013-11-27 | 2014-02-26 | 桂林益元素生物科技有限公司 | Method for extracting hesperidin from orange peels |
CN104119411A (en) * | 2014-08-12 | 2014-10-29 | 四川天予植物药业有限公司 | Method for preparing high-purity hesperidin |
CN104262430A (en) * | 2014-09-24 | 2015-01-07 | 王红莲 | Method for extracting aurantiamarin from immature bitter orange |
Non-Patent Citations (1)
Title |
---|
吕扬 等: "《晶型药物》", 31 October 2009 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018010170A1 (en) * | 2016-07-15 | 2018-01-18 | 刘力 | Novel embodiment of flavonoid, and composition and application thereof |
CN108042557A (en) * | 2017-12-07 | 2018-05-18 | 珠海霍普金斯医药研究院股份有限公司 | Aurantiamarin is preparing the application in treating diabetic gangrene drug |
CN109549947A (en) * | 2019-01-25 | 2019-04-02 | 广州中健健康科技有限公司 | A kind of eye spray of anti-blue light and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2652187T3 (en) | L-Ornithine Phenylacetate and methods to make it | |
EP2128125B1 (en) | Caffeoyl quinic acid derivatives containing nitrogen, and preparation method, pharmaceutically composition and usage thereof | |
JP6517206B2 (en) | Novel therapeutic agent for pulmonary fibrosis, method of adjusting the same | |
NZ715029A (en) | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
JP2015516951A (en) | Tranilast composition and co-crystal | |
JP4654187B2 (en) | Isoflavone derivatives of tectorigenin, their preparation, and antiviral agents containing them as active ingredients | |
JP2019509332A (en) | Baicalin magnesium compound, its production method and use | |
CN104628796A (en) | Gastrodin medicine, and composition and use thereof | |
CN105837646A (en) | Flavonoid new chemical entity, composition and use | |
WO2016019683A1 (en) | Phillygenin ibuprofen ester, preparation method therefor, and applications thereof | |
CN101314579B (en) | Waterless Peramivir crystal and medicament composition thereof | |
JP2010528063A (en) | Method and use for obtaining an extract containing sequoyitol from a plant belonging to the genus Rhododendron, soybean, genus Ginkgo | |
KR101962189B1 (en) | Co-crystals of Aripiprazole and methods of preparing thereof | |
JP2014201590A (en) | Stilbenoid compound as inhibitor for squamous cell carcinoma and hepatoma and uses thereof | |
CN103992219B (en) | Hydroxyl amyl group Potassium Benzoate crystal and preparation method thereof | |
WO2011062640A1 (en) | Compounds as l-cystine crystallization inhibitors and uses thereof | |
CN105566316A (en) | Dibenzo quinolizine compound entity and application thereof | |
CN102746183B (en) | Tigecycline crystalline hydrate, preparation method thereof and uses thereof | |
CN102875615A (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
CN105461713A (en) | New benzonaphthyridine compound, and composition and use thereof | |
CN103382214B (en) | A kind of Tanshinone II A phosphoric acid phenol ester derivative and preparation method thereof | |
CN105646520A (en) | Stable Halaven compound | |
CN102351835B (en) | Mangiferin aglycone crystal forms, and composition, preparation method and application thereof | |
CN102659644B (en) | Crystal forms of 2-aminoethyl sulfonic acid and preparation processes for crystal forms | |
CN107586293A (en) | Sulfur-bearing dibenzothiazine alkaloid compound and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |